The IMpower010 trial demonstrates that atezolizumab significantly improves disease-free survival in resected, early-stage NSCLC patients compared to best supportive care. Tumors expressing PD-L1 > 50% show a greater benefit of treatment.
Two phase III trials by VHIO researchers reveal significant clinical activity of trastuzumab deruxtecan in HER2-positive metastatic breast cancer, with over half of patients experiencing two years without disease progression. Trastuzumab duocarmazine also shows promise in treating HER2-negative breast cancer and other tumor types.
Researchers at Vall d'Hebron Institute of Oncology are conducting a first-in-human Phase I trial to evaluate the safety and efficacy of Peptomyc's novel Myc inhibitor Omomyc in treating advanced solid tumors. The trial aims to confirm the compound's therapeutic potential, particularly for patients with progressed disease.
The CCE-DART project aims to develop interconnected tools to reduce the complexity of investigator-initiated trials, incorporating cutting-edge digital technologies. It will harmonize molecular multi-tier profiling platforms to precisely match patients to novel anti-cancer medicines based on genetic tumor specificities.
Researchers have identified a novel method using immune cells in cerebrospinal fluid to predict response to immunotherapy for patients with brain metastases. The analysis reveals similarities between immune cells in cerebrospinal fluid and those in brain metastasis, providing valuable insights into tumor microenvironment characterization.
Researchers have identified a novel mechanism of resistance to immunotherapy targeting HER2, where cancer cells adopt a strategy to evade clearance by redirected lymphocytes. The study found that disrupting interferon-gamma signaling confers resistance to these immunotherapies, promoting disease progression.
A proof-of-concept study shows cerebrospinal fluid as a liquid biopsy for precise characterization and real-time tracking of medulloblastoma. Circulating tumor DNA analysis provides genomic insights into disease evolution, enabling more effective treatment strategies.
The PROfound trial demonstrates the efficacy of PARP inhibitor olaparib in treating metastatic castration-resistant prostate cancer (mCRPC) with at least one alteration in BRCA1 or BRCA2 genes. Olaparib significantly improves overall survival, particularly in patients with alterations in these genes.
A new approach to identifying killer T lymphocytes in patients with gastrointestinal tumors has been developed, which can hone in on unique mutations expressed in cancer cells. This breakthrough could lead to the development of personalized and effective cell therapies for patients who do not respond to current immunotherapies.
A phase III study showed that the combination of encorafenib, binimetinib, and cetuximab significantly improved overall survival (9.0 months) and objective response rates compared to standard care. The treatment was well-tolerated, suggesting a potential paradigm shift in treating BRAF-mutant metastatic colorectal cancer.
A new study presents promising results from the CheckMate 358 trial, a phase I/II investigational immune-therapy trial combining nivolumab and ipilimumab for recurrent and metastatic cervical cancer. The combination showed higher clinical benefit rates compared to single-agent treatments.
A novel therapy with a dual mechanism of action has been shown to reactivate the anti-cancer alarm system, eliminating cancer stem cells and activating the immune system. Combining LIF-neutralizing antibodies with immunotherapy promotes tumor regression, triggers immune memory, and increases survival in animal models.
Researchers have developed a mini-protein MYC inhibitor that effectively treats non-small cell lung cancer, exhibiting minimal side effects. The therapy works by targeting the MYC oncogene, leading to reduced tumor growth and improved patient outcomes.
Researchers have developed a novel T cell bispecific antibody that guides immune cells to HER2-positive breast cancer cells, offering a targeted and safe approach. The therapy has shown promise in tackling certain breast cancers by exclusively targeting cancerous cells.
Researchers identify epigenetic enzyme TET2 as a key player in controlling dormant tumor cells that can lead to cancer recurrence. A novel biomarker, 5-Hydroxymethylcytosine (5hmC), is also discovered to detect these treatment-resistant cells and predict patient outcomes.
A recent study revealed that patients with inherited DNA repair mutations in metastatic prostate cancer can derive similar benefits from treatment with standard therapies as other patients. Ongoing research explores the potential potency of targeted therapy with PARP inhibitors, which may offer additional therapeutic options for these ...
A study published in JAMA Oncology shows that intrinsic molecular subtyping of breast cancer can predict patient outcomes and guide treatment decisions. The research found that the genomic classification of tumors is a key prognostic factor, outperforming traditional variables such as age and number of metastases.
Researchers propose using cerebrospinal fluid as a liquid biopsy for early diagnosis, prognosis, therapeutic management, and tracking of brain cancer. Concentrations of circulating central nervous system tumor DNA are higher in CSF than in plasma.
A large trial shows liquid biopsy (BEAMing technology) detects tumor genotypes not found in tissue biopsies, enabling targeted therapy selection. Regorafenib benefits patients with KRAS and PIK3CA mutations, revolutionizing colorectal cancer treatment.
Research at VHIO confirms Myc inhibition as a sound and effective therapeutic strategy for glioma, with no evidence of resistance or side effects. The study reveals new insights into the biology of Myc and its potential to halt normal cell division, leading to tumor cell death.
Researchers identified four subtypes of HER2+ breast cancer, including Luminal A, Luminal B, HER2-enriched, and Basal-Like, with varying responses to anti-HER2 therapy and chemotherapy. The study suggests that personalized treatment strategies may improve treatment outcomes for patients.
A multicentre phase III study shows that the nab-paclitaxel/gemcitabine combination significantly improves one- and two-year survival rates in patients with advanced pancreatic cancer compared to gemcitabine alone. This new drug combination is set to become a reference treatment for this disease.
Researchers Dr. Joan Seoane and Dr. Eduard Batlle from Barcelona have been recognized for their outstanding contributions to cancer research, with a focus on brain cancer and colorectal tumors. Their work aims to identify tumor stem cells and develop new therapeutic strategies to block metastasis.
A phase III study published in The Lancet found that ramucirumab inhibits tumour growth and improves median survival, offering new treatment options for patients with advanced gastric cancer. The study's results suggest a potential benefit for patients with limited treatment options.
Researchers at Vall d'Hebron Institute of Oncology have successfully eliminated mouse lung tumors by inhibiting the Myc protein, a key regulator of gene expression and cell growth. The study confirms that Myc-targeted therapy is a safe and effective option for treating various types of cancer, with no signs of resistance or side effects.
A Phase I clinical trial demonstrated the therapeutic effect of RNAi gene silencing in treating advanced cancer patients. The drug, ALN-VSP, presented good evidence for clinical utility and showed significant tumor response in 11 out of 37 patients.
A recent study by Vall d'Hebron Institute of Oncology has led to the redefinition of hormone-sensitive breast tumours, improving diagnosis and treatment outcomes. Gene expression analysis revealed discrepancies between histopathological data and molecular profiles, prompting a new definition that incorporates progesterone receptor levels.
Researchers have discovered biomarkers that predict response to treatment and proposed therapeutic solutions for patients who do not respond well. The study identifies the molecular mechanisms determining patients' response to certain drugs used in clinical trials.
A study by Vall d'Hebron Institute of Oncology reveals a potential new strategy to boost efficacy and break down resistance in patients with HER2 positive breast cancer. The combination of two drugs shows promise as a third treatment option, offering hope for patients with advanced tumours.
The USP15 protein has been identified as a critical regulator of cancer progression and immune response, accelerating drug development against glioblastoma and other types of cancer. USP15 promotes tumor growth by activating the TGFβ pathway, but its inhibition can lead to decreased TGFβ activity and reduced tumor development.
The BBVA Foundation-funded Tumor Biomarkers Research Program aims to develop targeted therapies for various types of cancer, including colorectal, breast, and lung cancer. The program will utilize biomarkers to identify unique molecular characteristics in each patient's tumor.
Researchers confirm vitamin D's role in slowing down colon cancer cell growth and proliferation. The study found that a lack of vitamin D increases the aggressiveness of colon cancer, highlighting its potential as an anti-tumor agent.